Gemcitabine and vinorelbine treatment in cutaneous T-cell lymphoma in four patients.
Azura Mohd AffandiTatiana Pinto BlumettiJillian WellsMark HertzbergPablo Fernandez-PenasPublished in: The Australasian journal of dermatology (2014)
Treatment options for advanced stage cutaneous T-cell lymphoma (CTCL) are limited by the their efficacy and side-effects profile. Gemcitabine, a pyrimidine analogue, has been reported to be efficacious in CTCL. Most of the studies published used gemcitabine as a single agent in treating advanced CTCL. Our small case series demonstrated that a combination of gemcitabine and vinorelbine induced partial remission in all four patients with refractory or advanced CTCL, although the effects were not sustained for a long duration (2-6 months). Two patients had neutropenia and one had acute hepatitis, requiring discontinuation of treatment.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- randomized controlled trial
- radiation therapy
- clinical trial
- intensive care unit
- systematic review
- drug induced
- acute respiratory distress syndrome
- respiratory failure
- extracorporeal membrane oxygenation
- double blind
- meta analyses